Newsletter · · Ashutosh Agarwal
The Obesity-Drug Pipeline - Week of June 22, 2026: Retatrutide hits 28% weight loss; Lilly dethrones Keytruda
GLP-1 and obesity-drug newsletter for the week of June 22, 2026. ADA 2026 broke decisively Lilly's way: retatrutide's TRIUMPH-1 posted near-surgical weight loss, the tirzepatide franchise displaced Keytruda as the world's top-selling drug, and contaminated placebo arms quietly became a regulatory problem for everyone chasing the leader.
The Obesity-Drug Pipeline
Week of June 22, 2026: Retatrutide hits 28% weight loss; Lilly dethrones Keytruda
ADA 2026 was the whole week, and it broke decisively one way. Lilly's triple-agonist retatrutide put up numbers that brush against bariatric surgery, the tirzepatide franchise knocked Keytruda off the top of the global drug-sales chart, and Novo's quarter went the other direction. Meanwhile the pipeline's dirty secret, patients keep wandering off placebo arms onto their own GLP-1s, quietly became a regulatory problem for everyone behind Lilly.
TL;DR
- Retatrutide is the new bar. TRIUMPH-1 delivered 28.3% weight loss (70.3 lbs) over 80 weeks, nearly half of patients past 30%, "encroaching on the outcomes we'd otherwise see with surgical options," per ADA's CSO (JAMA Medical News).
- Lilly's franchise is the biggest drug on earth. Q1 2026: Mounjaro $8.66B + Zepbound $4.16B = $12.8B; Mounjaro displaced Keytruda as #1 by quarterly sales. Novo's Ozempic and Wegovy both fell sequentially (Citeline / Scrip).
- Payers are blinking. CVS Caremark is restoring Zepbound coverage, reversing last summer's exclusion after an ERISA class-action and patient backlash (CareTalk).
What's new
Retatrutide redefines the efficacy ceiling. On JAMA Medical News ("Highlights From the ADA's 2026 Scientific Sessions"), Dr. Rita Kalyani, ADA Chief Scientific & Medical Officer, walked through two Lilly Phase 3 reads: TRANSCEND T2D-1 showed "up to a 2% reduction in A1c and a 16.8%... average loss of 36.6 pounds," and TRIUMPH-1 in obesity hit "28.3% over 80 weeks... on par with metabolic or bariatric surgery," with patients still losing out to 140 weeks. This resets the competitive ceiling for the entire next-gen field.
The tirzepatide franchise becomes the world's biggest drug. On Citeline's "Scrip's Five Must-Know Things, June 22", Mounjaro Q1 sales of $8.66B "more than doubling year-on-year," ex-US sales of $4.4B overtaking US for the first time, displacing Keytruda as #1. Full-year consensus: Mounjaro $33.1B, Zepbound $19.3B, four GLP-1 brands combining for ~$80B. Ozempic is "forecast to drop from third place in 2025 to seventh."
Novo's quarter went the wrong way. Same episode: Ozempic fell $602M and Wegovy fell $551M versus Q4 2025, partly seasonal, partly "a modest shift towards the recently launched oral Wegovy formulation." Cannibalizing your own injectable is fine; losing share to Lilly while doing it is not.
A payer reversal worth watching. On CareTalk: Healthcare. Unfiltered. ("The Business & Science Behind the GLP-1 Boom"), host David Williams and John Driscoll, Chairman of UConn Health, flagged CVS Caremark "restoring coverage of Zepbound, reversing a formulary decision from last summer... which prompted patient anger and a class action lawsuit" alleging ERISA violations. The exclusion lever has legal costs: bullish for net volume, bearish for the "payers will crush price" thesis.
The placebo problem is now a pipeline risk. Across On The Pen and Scrip, the recurring ADA theme: placebo arms are contaminating as patients start their own GLP-1s. Boehringer/Zealand's cervidutide saw ~16% of placebo patients go on GLP-1s in Synchronized 1, dragging the arm to -5.4% and "casting doubt on whether Boehringer Ingelheim will submit." Roche's CT-388 had 34% of its placebo arm drop out. Clean Phase 3 reads are getting structurally harder for everyone behind Lilly.
The debate
Bull: The TAM keeps compounding. ADA showed efficacy still climbing toward surgical outcomes (retatrutide 28%), indications fanning out (CVD, MASH, sleep apnea, plus early signals in long COVID via NIH RECOVER and oncology at ASCO 2026, per CareTalk), and payers retreating from exclusions under legal pressure. On Conversations on Health Care, Dr. Jamie Ard of Wake Forest called it "a watershed moment" with "roughly 110 million Americans eligible." Penetration is still single digits.
Bear: Demand isn't the question, durability and price are. Real-world persistence is ugly: CareTalk cited "50%... dropped them within six months" and "about 60% of weight loss... regained within a year after stopping," while BNY's guest put first-year discontinuation at "80% or more" (Double Take, BNY Investments Newton). Add a crowded next-gen field, compounded GLP-1s that didn't die when the shortage ended (scripts still rose through Oct 2025), and Brazil-style patent/compulsory-licensing erosion, and net price per script compresses faster than Street models assume.
Our read: This week widened the gap between the leader and everyone else. Lilly is pulling away on both efficacy and revenue; the bear case is increasingly a second-tier story about persistence and price for the followers, not the franchise.
Stocks in play
| Ticker | Bull case | Bear case | Next catalyst |
|---|---|---|---|
| LLY | Retatrutide 28% weight loss; franchise now world's #1 drug | Persistence/regain caps real-world value; prices perfection | Retatrutide filing; more ADA/EASD reads (JAMA) |
| NVO | Oral Wegovy launch; CagriSema Re-imagined hit 13.6% weight loss | Ozempic -$602M, Wegovy -$551M QoQ; CagriSema tolerability (60–69% completed top dose) | CagriSema path; oral Wegovy ramp (On The Pen) |
| Roche (RHHBY) | CT-388 dual agonist still in the mix | 34% placebo-arm dropout muddies the read | Cleaner CT-388 data (Scrip) |
| CVS | Caremark Zepbound reinstatement = more covered scripts | ERISA litigation cut both ways | 2027 formulary design (CareTalk) |
| PFE | Oral GLP-1 "faster weight loss than weekly Ozempic" | Far behind on data and scale | Oral GLP-1 late-stage reads (Conversations) |
Read-throughs
- Fast-followers (AMGN, VKTX, Roche): Amgen MariTide and Viking VK2735 drew zero coverage this week, notable for an ADA week. Roche's CT-388 surfaced only as the placebo-dropout cautionary tale. The retatrutide bar raises the "good enough to compete" threshold for all three.
- Contract manufacturing / fill-finish (CTLT, LNZA, TMO): Silent, no capacity or buildout chatter despite the volume ramp. Silence is data.
- Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize): Silent. The oral-formulation shift (oral Wegovy, orforglipron, Pfizer's pill) is the structural overhang to watch, but nothing new this week.
- Insurers / PBMs (CVS, CI, UNH): Only CVS active, via the Caremark reversal. Cigna/Express Scripts and UNH/Optum Rx quiet.
- Medtech / bariatric: No direct names, but retatrutide framed as "on par with... bariatric surgery," a structural negative read-through for procedure volumes.
- Food / QSR: Silent.
What changed vs. last week
Issue #1 of the series, no prior issue to diff against. Baseline set: Lilly leads on efficacy and revenue; Novo declining sequentially; CVS reversing on coverage; placebo contamination emerging as a cross-pipeline risk. Quiet this week and worth watching for movement: Novo CMD/CEO commentary, MariTide and VK2735, contract-manufacturing and pen-supplier capacity, and state-level Rx legislation.